ClinicalTrials.gg
CompletedNCT04868162Updated Sep 10, 2026

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

A Phase 2 interventional study of MRG003 and MRG003+HX008 in Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck, sponsored by Lepu Biopharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Squamous Cell Carcinoma of Head and Neck.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Lepu Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck — 15 open to participants now, 15 under way, 2 of them phase 3. becotatug vedotin · Squamous Cell Carcinoma of Head and Neck.

Enrollment
5th of 16
70 · median 52
Started
2021
the only one that year
Phase 2
13 of 16
12 open now
Registered
1st of 16
by date
Lead sponsor
3 of 16
Lepu Biopharma Co., Ltd.

Among the 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck, this one is the 5th largest by enrollment, is the only one that started in 2021, is one of 13 in phase 2, and was the 1st registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

15 of the 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

About becotatug vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.

Read the detailed description

The study consists of two stages. In Part A, approximately 60 patients will be enrolled to evaluate the safety and preliminarily efficacy of MRG003 at 2.0 and 2.3 mg/kg, to further explore the optimized dose. In Part B, 30 to 50 patients will be enrolled to evaluate the safety and preliminary efficacy of the combination of MRG003 and HX008.

03

Conditions studied

  • Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Browse trials for

Keywords

  • MRG003
  • Squamous Cell Carcinoma of Head and Neck
  • EGFR
  • HX008
  • PD-1
04

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's enrollment of 70 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

Lepu Biopharma Co., Ltd. is the lead sponsor of 16 studies on the registry; 9 are open to participants now.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to sign the ICF and follow the requirements specified in the protocol.
  • Expected survival time≥3 months.
  • Patients with confirmed unresectable recurrent or squamous cell carcinoma of head and neck.
  • Failed prior platinum and/or treatment (Part A); failed or intolerant to at least one prior line of standard therapy (platinum-based regimen) (Part B)
  • Patients must have at least one according to the (RECIST v1.1).
  • performance score 0 or 1.
  • Organ functions and coagulation function must meet the basic requirements.
  • Serum or urine pregnancy test negative within 7 days before the first dose of drug.
  • Patients with must use effective during the treatment and for 6 months after the last dose of treatment.

Exclusion criteria

Exclusion Criteria:

  • History of 4 or more systemic anti-tumor therapies for the recurrent or squamous cell carcinoma of head and neck.
  • ≥Grade 2 peripheral neuropathy
  • Prior anti-tumor therapy with MMAE/MMAF ADCs
  • ≤17
  • Expected surgery or any other form of systemic or local anti-tumor therapy.
  • History of systemic chemotherapy within 3 weeks before the first administration of the drug, targeted small molecule therapy within 2 weeks or 5 half-life periods before the first administration (whichever is shorter), antitumor biological therapy or immunotherapy within 4 weeks before the first administration, or major surgery.
  • Known active and/or cancerous meningitis.
  • Residual toxicity reactions caused by previous anti-tumor treatment or abnormal values of laboratory tests higher than grade 1 ( v5.0). Prior Grade 3 to 4 immune-related AE (irAE) or ≥Grade 2 heart-related irAE.
  • Uncontrolled or poorly controlled heart disease.
  • History of pulmonary embolism or deep vein thrombosis within 3 months before the first administration of the investigational drug.
  • Known history of .
  • History of severe dermatosis.
  • Uncontrolled or poorly controlled hypertension.
  • Patients with a history of active bleeding, coagulopathy, or receiving coumarin anticoagulation therapy.
  • Known allergic reaction to any ingredients or of investigational drugs.
  • Known active or C.
  • Complicated with severe, uncontrolled infection or known (HIV) infection, or diagnosed as acquired immunodeficiency syndrome (AIDS); or uncontrolled disease; or history of allogeneic tissue/organ transplantation, stem cell or bone marrow transplantation, or solid organ transplantation.
  • Active bacterial, viral, fungal, rickettsia, or parasitic infections that require systemic anti-infective treatment.
  • Vaccination of within 30 days before the first administration of the study drug. Inactivated seasonal influenza vaccine or approved COVID-19 vaccine is allowed.
  • History of previous or concurrent interstitial pneumonia, radiation pneumonitis, severe , severe pulmonary dysfunction, symptomatic bronchospasm, etc.
  • Patients receiving immunology-based treatment for any reason.
  • Uncontrolled pleural effusion, pericardial effusion or recurrent ascites.
  • Potent inhibitors or inducers are in use and cannot be discontinued.
  • Women who are lactating or pregnant.
  • Other conditions that in the clinical judgement of the investigator make the patient not suitable for participation in this study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    MRG003 monotherapy will be administered for patients enrolled into Part A of this study; MRG003 and HX008 combination will be administered for patients enrolled into Part B of this study.

    Drug: MRG003 · Drug: MRG003+HX008

Interventions

  • DrugMRG003

    On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or 2.3 mg/kg.

  • DrugMRG003+HX008

    Drug pages: Becotatug vedotin · Pucotenlimab

    On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or the recommended dose by SMC; and HX008 will be administered via intravenous infusion at 3.0 mg/kg

07

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) by Investigator per RECIST v1.1

    ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed according to RECIST v1.1.

    Time frame: Baseline to study completion (up to 24 months)

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR is defined as the proportion of subjects achieving CR, PR, and stable disease (SD) after treatment.

    Time frame: Baseline to study completion (up to 24 months)

  2. Duration of Response (DoR)

    The time interval between the date of the earliest qualifying response and the date of disease progression or death for any cause, whichever occurs earlier.

    Time frame: Baseline to study completion (up to 24 months)

  3. Progression Free Survival (PFS) as assessed by investigator

    PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  4. Overall Survival (OS)

    OS is defined as the duration from the start of treatment to death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  5. Adverse Events (AEs)

    Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.

    Time frame: Baseline to 30 days after the last dose of study treatment

  6. Serious Adverse Events (SAEs)

    Adverse events that are fatal, life-threatening, or result in hospitalization or prolonged hospitalization, persistent or significant disability/incapacity/substantial disruption of the ability to lead a normal life, congenital anomaly/birth defect or major medical events or reactions

    Time frame: Baseline to 45 days after the last dose of study treatment

  7. Tmax

    Time to reach the maximum blood concentration

    Time frame: Baseline to 30 days after the last dose of study treatment

  8. Cmax

    Maximum observed blood concentration

    Time frame: Baseline to 30 days after the last dose of study treatment

  9. AUClast

    Area under the blood concentration-time curve from time 0 to the time of last quantifiable concentration

    Time frame: Baseline to 30 days after the last dose of study treatment

  10. Incidence of anti-drug antibody (ADA)

    The proportion of patients with positive ADA immunogenicity results.

    Time frame: Baseline to 30 days after the last dose of study treatment

08

Study locations

1 site
  • Shanghai East Hospital
    Shanghai, Shanghai Municipality 200123, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jul 2024, 39 months.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 39 months is close to that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
Apr 30, 2021
StartActual
Apr 23, 2021
Primary completionActual
Jul 26, 2024
CompletionActual
Jul 26, 2024
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04868162
Lead sponsor
Lepu Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Apr 30, 2021
Start date
Apr 23, 2021
Primary completion
Jul 26, 2024
Completion
Jul 26, 2024
Last update
Sep 10, 2026

Study contacts

Ye Guo, Doctor
principal investigator · Shanghai East Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Becotatug vedotin

Start the discussion